Neoadjuvant chemotherapy plus trastuzumab in stage II/III breast cancer with low HER2 expression

被引：1
|
作者：
Khan, Qamar J.
O'Dea, Anne
Fabian, Carol J.
Connor, Carol Sue
McGinness, Marilee
Mammen, Joshua Matthew Varghise
Wagner, Jamie Lynn
Baccaray, Stella
Springer, Michelle
Yeh, Henry
Sharma, Priyanka
机构：
[1] Univ Kansas Med Ctr, Kansas City, KS USA
[2] Drieling Schmidt Canc Inst, Hays, KS USA
[3] Univ Kansas Med Ctr, Westwood, KS USA
[4] Univ Kansas, Kansas City, KS USA
[5] Univ Kansas, Olathe, KS USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.1039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1039
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomized phase II study of neoadjuvant chemotherapy and trastuzumab for operable breast cancer with overexpression of HER2
    Masuda, N.
    Ando, M.
    Aogi, K.
    Ino, H.
    Iwata, H.
    Tokuda, Y.
    Nakamura, S.
    Yamamoto, N.
    Fujiwara, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
    Carsten Denkert
    Jens Huober
    Sibylle Loibl
    Judith Prinzler
    Ralf Kronenwett
    Silvia Darb-Esfahani
    Jan C Brase
    Christine Solbach
    Keyur Mehta
    Peter A Fasching
    Bruno V Sinn
    Knut Engels
    Mattea Reinisch
    Martin-Leo Hansmann
    Hans Tesch
    Gunter von Minckwitz
    Michael Untch
    Breast Cancer Research, 15
  • [3] HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
    Denkert, Carsten
    Huober, Jens
    Loibl, Sibylle
    Prinzler, Judith
    Kronenwett, Ralf
    Darb-Esfahani, Silvia
    Brase, Jan C.
    Solbach, Christine
    Mehta, Keyur
    Fasching, Peter A.
    Sinn, Bruno V.
    Engels, Knut
    Reinisch, Mattea
    Hansmann, Martin-Leo
    Tesch, Hans
    von Minckwitz, Gunter
    Untch, Michael
    BREAST CANCER RESEARCH, 2013, 15 (01)
  • [4] HER2 overexpression predicts survival in stage II and III of breast cancer patients treated with neoadjuvant docetaxel plus epirubicin
    不详
    VIRCHOWS ARCHIV, 2005, 447 (02) : 364 - 365
  • [5] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [6] Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer
    Fujita, Tetsuji
    LANCET, 2012, 379 (9833): : 2237 - 2237
  • [7] Neoadjuvant treatment of stage II or III breast cancer with docetaxel and low dose capecitabine, with addition of trastuzumab for HER 2 amplified tumors
    Khan, Q. J.
    Sharma, P.
    Kimler, B. F.
    Baranda, J.
    Andersen, J. C.
    Klemp, J.
    Fabian, C. J.
    BREAST, 2007, 16 : S49 - S49
  • [8] Influence of EIF4E and HER2 Protein Expression on the Response to Neoadjuvant Chemotherapy and Trastuzumab in Breast Cancer
    Berge, Y.
    Filleron, T.
    Zindy, P.
    Charitansky, H.
    Gaston, A.
    Silvagni, C.
    Roche, H.
    Vagner, S.
    Lacroix-Triki, M.
    Dalenc, F.
    CANCER RESEARCH, 2009, 69 (24) : 606S - 606S
  • [9] Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-PositiveBreast Cancer: A PhaseIIClinical Trial
    Xuhong, Juncheng
    Qi, Xiaowei
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Zhang, Fan
    Tan, Xuanni
    Yan, Wenting
    Zhong, Ling
    He, Cheng
    Liang, Yan
    Ren, Lin
    Wang, Minghao
    Zhang, Yi
    Jiang, Jun
    ONCOLOGIST, 2020, 25 (12): : E1909 - E1920
  • [10] Correlation between HER2 amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2 positive breast cancer.
    Antolin, Silvia
    Garcia-Caballero, Lucia
    Reboredo, Cristina
    Molina Diaz, Aurea
    Mosquera, Joaquin
    Vazquez-Boquete, Angel
    Gallego, Rosalia
    Paz Santiago, Maria
    Concha, Angel
    Eva Perez, Maria
    Calvo, Lourdes
    Garcia-Caballero, Tomas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345